2008-05-29 22:49:19 -
www.researchandmarkets.com - Research and Markets (www.researchandmarkets.com/reports/c93075) has announced the addition of Thought Leader Insight & Analysis: Type 2 Diabetes to their offering.
The major theme for this report is the interplay between diabetes and cardiovascular disease; specifically coronary artery disease.
- Recent changes to the ADA guidelines highlight the diabetic's increased risk for CAD. In light of these
guidelines our Panel discusses the unmet needs and the endocrinologist's emerging therapeutic management strategies for diabetes, CAD, metabolic syndrome and nonalcoholic steatohepatitis (NASH).
- Incretins will dominate new launches for HbA1c lowering drugs for the next few years. The Panel discusses the significance of targeting DPP4, DPP8 and DPP9, and compares this class with GLP-1 agonists. Strengths and weaknesses of new monotherapies and combination approaches are discussed.
- These new orals and parenterals will put pressure on established products, including metformin, sulfonylureas and TZDs. The Panel offers insight into how each fits into the diabetes / CAD paradigm.
- Exubera established the proof-of-concept for non-injectable insulin therapy. The Panel describes why it has failed commercially, and benchmarks next-generation insulins.
- The other new mechanism most of interest to the Panel was inhibition of SGLT. While still very early in development the Panel shared key insights about the future for this class.
- Finally, the Panel comments on the importance of Beta cell protection or regeneration. -0- Executive Summary Report Highlights Key Findings - Diabetes and Coronary Artery Disease - Biguanide - Metformin Incretins DPP - Januvia / Janumet (sitagliptin; Merck) - Galvus (vildagliptin; Novartis) - alogliptin (Takeda) - saxagliptin (BMS/AZ) - Redona (denagliptin; GSK) GLP-1 - Byetta (exenatide; Amylin/Lilly) - Exenatide LAR (Lilly/Amylin/Alkermes) - Symlin (pramlintide; Amylin) - Pramlintide + Recombinant Leptin (r-metHuLeptin) (Amylin/Amgen) - Liraglutide (NN2211; Novo Nordisk) - Next Generation Oral GLP1 Agonists PPAR - Actos (pioglitazone; Takeda/Lilly) - Avandia (rosiglitazone; GSK) - Next Generation PPARs Secretagogues - Sulfonylureas SGLT Insulins - Non-Injected Insulin Formulations For T2Ds - Unmet Needs - Inhaled: Exubera (Nektar) - Inhaled: AIR Insulin (Lilly/Alkermes) - Inhaled: Technosphere(R) Insulin System (Mannkind) - Inhaled: AERx (Novo Nordisk / Aradigm) - Oral: Oral-lyn; Generex / Lilly Beta Cell Survival / Regeneration Thought-Leader Discussions - Interview BJE01942 - Interview BJE01943 - Interview BJE01944 - Interview BJE01945 - Interview BJE01946 - Interview BJE01947 Products Mentioned: - metformin - Januvia/Janumet (sitagliptin; Merck) - Byetta (exenatide; Lilly/Amylin) - exenatide LAR (Lilly/Amylin/Alkermes) - Symlin (Amylin) - pramlintide + leptin (Amylin/Amgen) - Galvus (vildagliptin; Novartis) - alogliptin (Takeda) - saxagliptin (BMS/AZ) - Redona (denagliptin; GSK) - liraglutide (Novo Nordisk) - Boc5 (UC Riverside / Chinese Acad. Sci.) - substituted quinoxalines (Pfizer/Novo Nordisk) - Actos (pioglitazone; Takeda/Lilly) - Avandia (rosiglitazone; GSK) - Exubera (Nektar) - AIR Insulin (Lilly/Alkermes) - Technosphere (Mannkind) - AERx (Novo Nordisk/Aradigm) - Oral-lyn (Generex/Lilly) - buccal insulin (GSK)
For more information visit
www.researchandmarkets.com/reports/c93075.
Research and Markets Ltd.
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax: +353 1 4100 980
